cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Paratek Pharmaceuticals Inc
8 own
31 watching
Current Price
$2.23
$-0.04
(-1.76%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
123.63M
52-Week High
52-Week High
4.25
52-Week Low
52-Week Low
1.6
Average Volume
Average Volume
0.2M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization123.63M
icon52-Week High4.25
icon52-Week Low1.6
iconAverage Volume0.2M
iconDividend Yield--
iconP/E Ratio--
What does the Paratek Pharmaceuticals Inc do?
Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Read More
How much money does Paratek Pharmaceuticals Inc make?
News & Events about Paratek Pharmaceuticals Inc.
Globe Newswire
1month ago
Total Procurement-related Revenue Recognition of $38.1 Million to Paratek in December 2022Procurement Triggered by Positive Top-Line Data from Pilot Efficacy Study of NUZYRA for the Treatment of Pulmonary Anthrax Announced in December BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals...
Globe Newswire
1month ago
BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the Companys independent directors of the Board have appointed Jeffrey Stein, PhD as its first Lead Independent Director, effective December 8, 2022. Dr. Stein was selected unanimously by the ...
Globe Newswire
1month ago
100% Survival Rate in Anthrax-infected Rabbits Treated with OmadacyclineTotal Revenue Recognition to Paratek of $38.1 Million BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced positive top line data from a pilot rabbit efficacy study evaluating ...
Globe Newswire
3 months ago
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announces the commercial availability of U.S.-produced NUZYRA (omadacycline) tablets. This milestone follows a successful technology transfer by Paratek and its tablet manufacturing partners in the United ...
Globe Newswire
4 months ago
Oct. 3 Webinar Features Presentations by Scientific Leaders in NTM and Parateks Management TeamBOSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving ...
Frequently Asked Questions
Frequently Asked Questions
What is Paratek Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Paratek Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Paratek Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Paratek Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Paratek Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Paratek Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Paratek Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Paratek Pharmaceuticals Inc?
plus_minus_icon
What percentage is Paratek Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Paratek Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$2.23
$-0.04
(-1.76%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$68.70
$-5.59 (-7.52 %)
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$3.15
$0.30 (10.53 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.90
$-0.05 (-1.69 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$6.53
$-0.12 (-1.88 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$68.70
$-5.59 (-7.52 %)
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$3.15
$0.30 (10.53 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.90
$-0.05 (-1.69 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$6.53
$-0.12 (-1.88 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00